The Synergistic Effects of Menopause and HIV on Cardiovascular Disease Risk in Women
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Whole body MRI.
- Who it may be relevant to
- Registry conditions: HIV, Menopause, Cardiovascular (CV) Risk, Carotid Arteriosclerosis. Basic parameters: from 18 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Menopause is associated with the acceleration of many comorbidities, including cardiovascular disease. Whether HIV and menopause together increase cardiovascular disease risk is a key knowledge gap. The goal of this observational study is to address this knowledge gap by looking at the role of menopause on cardiovascular disease risk factors such as insulin resistance, hypertension, hyperlipidemia, and carotid atherosclerosis using previously collected data. The investigators will look at underlying causes for cardiovascular diseases worsening in menopausal women with HIV by looking at the role of increased inflammation in the body and whether this is altered by weight. The investigators achieve this by enrolling participants who are willing to undergo a whole body MRI.
Interventions
- Diagnostic test Whole body MRI
Whole body MRI will be performed as part of a study protocol
Primary outcome measures
- Markers of immune activation and inflammation [Time frame: These markers will be measured from blood work collected at the scheduled study visit [Day 1] close to the time of MRI and thus will be collected at only one time point.]
Eligibility criteria
Inclusion criteria
- 90 non-pregnant women with HIV (approximately 30 in each menopausal phase) from the San Francisco MWCCS site.
Exclusion criteria
- Women who are not virally suppressed (HIV RNA >200 copies/mL)
- Women who are not on antiretroviral therapy
- Women who have a history of hysterectomy or oophorectomy
- Women who are receiving treatment for active cancer or tuberculosis
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
United States · 1 center
- University of California, San Francisco — San Francisco
Identifiers
NCT: NCT07284082 · 25-43802 · K23HL178394